Abstract
Roche and Synlogic have teamed up to test combining two immune-modulating cancer treatments: Roche’s PD-L1 checkpoint inhibitor Tecentriq and Synlogic’s SYNB1891, a strain of Escherichia coli engineered to express an agonist of STING, part of the innate immune system that drives the production of inflammatory proteins that, in turn, cause the adaptive immune system to kick into gear. Synlogic says it will ask the US Food and Drug Administration for the green light to begin human studies of SYNB1891 in the second half of this year.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
